Sacubright 100 A brand of sacubitril

Sacubitril , Valsartan
Sacubright 100 A brand of sacubitril

SACUBRIGHT 100 is a fixed-dose combination medication containing Sacubitril (49 mg) and Valsartan (51 mg). This innovative therapy is primarily used for the treatment of heart failure with reduced ejection fraction (HFrEF), a condition where the heart's ability to pump blood is weakened. SACUBRIGHT 100 combines two potent medications—Sacubitril, a neprilysin inhibitor, and Valsartan, an angiotensin II receptor blocker (ARB)—to provide a dual mechanism of action that enhances heart function and reduces symptoms associated with heart failure.

By combining these two drugs, SACUBRIGHT 100 offers a comprehensive approach to managing heart failure and improving patient outcomes. This article explores the composition, usage, benefits, and key features of SACUBRIGHT 100.

Key Features and Ingredients

• Active Ingredients:

  • Sacubitril (49 mg): Sacubitril is a neprilysin inhibitor that helps increase the levels of natriuretic peptides, which promote vasodilation (widening of blood vessels), reduce fluid retention, and lower blood pressure. By inhibiting neprilysin, Sacubitril improves heart function and reduces the strain on the heart.

  • Valsartan (51 mg): Valsartan is an angiotensin II receptor blocker (ARB) that works by blocking the action of angiotensin II, a hormone that causes blood vessels to constrict. By blocking this hormone, Valsartan helps lower blood pressure, reduces heart workload, and prevents further heart damage.

• Dual Mechanism of Action: The combination of Sacubitril and Valsartan works synergistically to improve heart function. While Sacubitril reduces fluid buildup and improves vasodilation, Valsartan lowers blood pressure and prevents harmful effects of angiotensin II, addressing the underlying causes of heart failure.

• Composition: Each tablet of SACUBRIGHT 100 contains:

  • Sacubitril: 49 mg

  • Valsartan: 51 mg

This combination is designed for easy administration, providing effective therapy for heart failure patients.

Usage

SACUBRIGHT 100 is primarily indicated for heart failure with reduced ejection fraction (HFrEF). It is commonly prescribed to patients with chronic heart failure to help improve symptoms, reduce hospitalizations, and decrease the risk of cardiovascular-related death.

Recommended Usage:

• The typical starting dose of SACUBRIGHT 100 is one tablet daily, as directed by your healthcare provider. The dose may be adjusted based on the patient's response to therapy and any potential side effects.

• It is usually taken orally with or without food, but patients should follow their doctor’s specific instructions regarding timing and dosage.

• It is essential to swallow the tablet whole, without crushing or breaking it, to ensure the medication's effectiveness.

Patients should also monitor their blood pressure and renal function regularly while on SACUBRIGHT 100, as changes in these parameters may require adjustments to the treatment regimen.

Benefits of SACUBRIGHT 100

1. Improved Heart Function: SACUBRIGHT 100 helps enhance heart function in patients with heart failure with reduced ejection fraction. The combination of Sacubitril and Valsartan works to improve cardiac output, increase blood flow, and reduce strain on the heart, leading to better overall heart health.

2. Reduced Hospitalization: Patients taking SACUBRIGHT 100 have shown a reduced risk of heart failure-related hospitalizations. By improving heart function and managing fluid retention, this medication helps prevent acute exacerbations that lead to hospitalization.

3. Lowered Blood Pressure: The Valsartan component of SACUBRIGHT 100 effectively reduces high blood pressure, which is a major contributor to heart failure. By lowering blood pressure, SACUBRIGHT 100 reduces the heart's workload and helps prevent further damage to the heart muscle.

4. Improved Symptoms: SACUBRIGHT 100 can help alleviate symptoms of heart failure, such as shortness of breath, fatigue, and swelling, improving the patient's quality of life. This combination therapy helps manage chronic heart failure more effectively than monotherapy.

5. Reduced Mortality Risk: Studies have shown that combining Sacubitril with Valsartan significantly reduces the risk of cardiovascular-related death. The dual action of these drugs provides better control of heart failure symptoms and helps prevent heart failure progression.

6. Convenient Dosage: SACUBRIGHT 100 is a fixed-dose combination tablet, making it easier for patients to adhere to their treatment plan. With just one tablet per day, patients can manage their condition without the need for multiple medications.

Side Effects and Safety Considerations

While SACUBRIGHT 100 is generally well-tolerated, like all medications, it can cause side effects. Some common side effects include:

• Low blood pressure (hypotension),

• Dizziness or lightheadedness,

• Elevated potassium levels (hyperkalemia),

• Angioedema (swelling of the face, lips, throat, or tongue),

• Fatigue or weakness.

In rare cases, more serious reactions such as kidney dysfunction or severe allergic reactions may occur. It is important for patients to monitor renal function and electrolyte levels during treatment.

Before starting SACUBRIGHT 100, patients should inform their doctor if they have a history of:

• Kidney disease,

• Liver problems,

• Angioedema (a history of swelling), or

• Pregnancy or breastfeeding (SACUBRIGHT 100 is not recommended during pregnancy).

Regular follow-up appointments are essential to ensure that SACUBRIGHT 100 is working effectively and to monitor for any potential side effects.

Conclusion

SACUBRIGHT 100 offers an effective and innovative solution for managing heart failure with reduced ejection fraction (HFrEF). By combining Sacubitril and Valsartan, this fixed-dose combination medication provides a dual mechanism of action that improves heart function, lowers blood pressure, and reduces the risk of hospitalizations. The once-daily dosage enhances patient adherence, making it an ideal option for long-term heart failure management. Steris Healthcare Pvt Ltd, known as Sterispharma, was founded in February 2018 by a team of experienced professionals in the pharmaceutical industry. Headquartered in Navi Mumbai, the company holds certifications from WHO, GMP, and ISO, reflecting its dedication to maintaining high standards of quality and safety. Sterispharma’s mission is to provide affordable, high-quality medications across India, strictly adhering to WHO guidelines. With the convenience of an online pharmacy, customers can easily order medicines with home delivery options. The company offers a wide range of healthcare products, catering to various medical needs, from rare disease treatments to essential healthcare products. Sterispharma's product range includes solutions for Cardiology, Asthma, Respiratory Issues, Nasal Conditions, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infectives/Antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental Care, and Dermatology. Medicines can be conveniently ordered via Our websites—Sterisonline, Sterisindia, and Sterispharma.

For further information 

Email: info@sterispharma.com / contact@sterispharma.com

Call/WhatsApp: 8209542042 , 8824175417

BUY NOW